Stephanie Lobaugh

Ms. Stephanie Lobaugh

orcid

Research Focus & Metrics

Academic Career Length

7Years (2020-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

17 March 2022 in European Urology Oncology
Verified
Journal Article
Closed access
DGDaniel Gorovets
Daniel Gorovets
AWAndreas G. Wibmer
Andreas G. Wibmer
AMAssaf Moore
Assaf Moore
SLStephanie Lobaugh
Stephanie Lobaugh
ZZZhigang Zhang
Zhigang Zhang
MZMichael J. Zelefsky
Michael J. Zelefsky

12 November 2020 in International Journal of Radiation Oncology, Biology, Physics
Verified
Journal Article
Closed access
PSPatricia Mae G. Santos
Patricia Mae G. Santos
KLKaitlyn Lapen
Kaitlyn Lapen
ZZZhigang Zhang
Zhigang Zhang
SLStephanie Lobaugh
Stephanie Lobaugh
CTC. Jillian Tsai
C. Jillian Tsai
EGErin F. Gillespie
Erin F. Gillespie

30 April 2024 in Journal of Clinical Medicine
Verified
Journal Article
Open access
PDF file
EDEdward Christopher Dee
Edward Christopher Dee
VNVictor C. Ng
Victor C. Ng
Eileen O'ReillyEileen O'Reilly
Eileen O'Reilly
AWAlice C Wei
Alice C Wei
SLStephanie Lobaugh
Stephanie Lobaugh
MRMarsha Reyngold
Marsha Reyngold
Introduction: The rate of isolated locoregional recurrence after surgery for pancreatic adenocarcinoma (PDAC) approaches 25%. Ablative radiation therapy (A-RT) has improved outcomes for locally advanced disease in the primary setting. We sought to evaluate the outcomes of salvage A-RT for isolated locoregional recurrence and examine the relationship between subsequent patterns of failure, radiation dose, and treatment volume. Methods: We conducted a retrospective analysis of all consecutive participants who underwent A-RT for an isolated locoregional recurrence of PDAC after prior surgery at our institution between 2016 and 2021. Treatment consisted of ablative dose (BED10 98–100 Gy) to the gross disease with an additional prophylactic low dose (BED10 < 50 Gy), with the elective volume covering a 1.5 cm isotropic expansion around the gross disease and the circumference of the involved vessels. Local and locoregional failure (LF and LRF, respectively) estimated by the cumulative incidence function with competing risks, distant metastasis-free and overall survival (DMFS and OS, respectively) estimated by the Kaplan–Meier method, and toxicities scored by CTCAE v5.0 are reported. Location of recurrence was mapped to the dose region on the initial radiation plan. Results: Among 65 participants (of whom two had two A-RT courses), the median age was 67 (range 37–87) years, 36 (55%) were male, and 53 (82%) had undergone pancreaticoduodenectomy with a median disease-free interval to locoregional recurrence of 16 (range, 6–71) months. Twenty-seven participants (42%) received chemotherapy prior to A-RT. With a median follow-up of 35 months (95%CI, 26–56 months) from diagnosis of recurrence, 24-month OS and DMFS were 57% (95%CI, 46–72%) and 22% (95%CI, 14–37%), respectively, while 24-month cumulative incidence of in-field LF and total LRF were 28% (95%CI, 17–40%) and 36% (95%CI 24–48%), respectively. First failure after A-RT was distant in 35 patients (53.8%), locoregional in 12 patients (18.5%), and synchronous distant and locoregional in 10 patients (15.4%). Most locoregional failures occurred in elective low-dose volumes. Acute and chronic grade 3–4 toxicities were noted in 1 (1.5%) and 5 patients (7.5%), respectively. Conclusions: Salvage A-RT achieves favorable OS and local control outcomes in participants with an isolated locoregional recurrence of PDAC after surgical resection. Consideration should be given to extending high-dose fields to include adjacent segments of at-risk vessels beyond direct contact with the gross disease.

23 May 2026 in Cancers
Verified
Journal Article
Open access
PDF file
COCamila Vilela de Oliveira
Camila Vilela de Oliveira
CLCorinne Liu
Corinne Liu
MMMaria Mayoral
Maria Mayoral
APAndrew M. Pagano
Andrew M. Pagano
EOEduardo Ortiz
Eduardo Ortiz
APAndrew Joseph Plodkowski
Andrew Joseph Plodkowski
Background/Objectives: Distinguishing primary lung squamous cell carcinoma (PLSCC) from metastatic head and neck squamous cell carcinoma (MHNSCC) to the lungs is challenging for pathologists, especially when patients present with a solitary lung nodule. The purpose of this study was to identify CT imaging features that differ between PLSCC from solitary MHNSCC to the lungs, using next-generation sequencing (NGS) and human papillomavirus in situ hybridization analysis as the gold reference standard. Methods: This retrospective, single-institution cross-sectional study included patients with a biopsy-proven PLSCC or solitary MHNSCC from July 2013 to May 2022, who underwent NGS or in situ hybridization, and baseline CT or PET/CT. Each scan was evaluated by at least two radiologists. Nodular, pleural, and ancillary CT features, as well as maximum standardized uptake value (SUVmax) from PET/CTs, were recorded. Associations between imaging features and pathology were examined using either the Wilcoxon rank-sum or Fisher’s exact test. Results: In total, 81 patients were included (median 66 years; 64 male); 36/81 (44%) had PLSCC and 45/81 (56%) had MHNSCC. PLSCC was associated with a larger size (median, 3.3–3.6 cm vs. 1.4–1.6 cm, p < 0.001), and the presence of post obstructive atelectasis (p = 0.002), pleural retraction (p < 0.001), pleural tags (p = 0.02), and pleural surface involvement (p = 0.02). MHNSCC presented as smaller peripheral nodules (p = 0.003) with lower SUVmax (p = 0.01). Conclusions: Several CT imaging features as well as SUVmax from PET/CT were significantly different between PLSCC and solitary MHNSCC and their potential discriminatory ability warrants evaluation in future studies.

23 October 2025 in Abdominal Radiology
Verified
Journal Article
Closed access
PDF file
MHMaria El Homsi
Maria El Homsi
HKHala khasawneh
Hala khasawneh
MAMohammad Ali El Amine
Mohammad Ali El Amine
JFJames Louis Fuqua
James Louis Fuqua
DHDina Hamdan
Dina Hamdan
JPJennifer S. Golia Pernicka
Jennifer S. Golia Pernicka